Literature DB >> 2078790

Surgical resection for cancer of the pancreas.

R C Russell.   

Abstract

Entities:  

Mesh:

Year:  1990        PMID: 2078790     DOI: 10.1016/0950-3528(90)90025-c

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


× No keyword cloud information.
  7 in total

1.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Authors:  J P Neoptolemos; P Baker; H Beger; K Link; P Pederzoli; C Bassi; C Dervenis; H Friess; M Büchler
Journal:  Int J Pancreatol       Date:  1997-04

3.  Celiac artery adjuvant chemotherapy. Results of a prospective trial.

Authors:  K H Link; F Gansauge; N Rilinger; H G Beger
Journal:  Int J Pancreatol       Date:  1997-02

4.  Pancreatic carcinoma accompanied by pseudocyst: report of two cases.

Authors:  W Kimura; N Sata; H Nakayama; T Muto; N Matsuhashi; K Sugano; Y Atomi
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

5.  Review of standards for reporting results of treatment of exocrine pancreatic cancer.

Authors:  A Andrén-Sandberg; C Cedercrantz
Journal:  Int J Pancreatol       Date:  1993-12

Review 6.  Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.

Authors:  F J Prott; K Schönekaes; P Preusser; K Ostkamp; W Wagner; O Micke; R Pötter; U Sulkowski; C Rübe; T Berns; N Willich
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease.

Authors:  S R Bramhall; G W Stamp; J Dunn; N R Lemoine; J P Neoptolemos
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.